Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa
Public ClinicalTrials.gov record NCT02022020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Observational Study Assessing the Management of Gastrointestinal and Urogenital Bleeding Events in Patients With Atrial Fibrillation Treated With Dabigatran Etexilate
Study identification
- NCT ID
- NCT02022020
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2013
- Primary completion
- Sep 30, 2015
- Completion
- Sep 30, 2015
- Last update posted
- Jan 30, 2017
2014 – 2015
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Aurora | Colorado | — | — |
| Boehringer Ingelheim Investigational Site | New Britain | Connecticut | — | — |
| Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| Boehringer Ingelheim Investigational Site | Springfield | Massachusetts | — | — |
| Boehringer Ingelheim Investigational Site | Chesterfield | Missouri | — | — |
| Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| Boehringer Ingelheim Investigational Site | Hackensack | New Jersey | — | — |
| Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| Boehringer Ingelheim Investigational Site | Staten Island | New York | — | — |
| Boehringer Ingelheim Investigational Site | Philedelphia | Pennsylvania | — | — |
| Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| Boehringer Ingelheim Investigational Site | Charlottesville | Virginia | — | — |
| Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
| Boehringer Ingelheim Investigational Site | Roanoke | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02022020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02022020 live on ClinicalTrials.gov.